



Soyfoods are common in Asian and many health-conscious Western diets, and thus it is pertinent to explore the safety of soy as documented in the body of accumulated research. Consumers can be encouraged to continue feeding their families soyfoods for generations to come.

Traditional soyfoods have played an important role in East Asian diets for centuries, and have been consumed by health-conscious individuals in Western countries for decades. More recently, soyfoods have become increasingly popular among mainstream consumers in the West, largely because of research suggesting they offer health benefits independent of the nutrients they provide.

Possible benefits include reduced risk of coronary heart disease,¹⁻³ osteoporosis,⁴⁻⁶ and some forms of cancer.⁷ Many of the proposed benefits of soyfoods are attributed to their uniquely rich isoflavone content. However, isoflavones, diphenolic molecules with estrogen-like properties, are also the primary reason for concerns about the potential adverse effects of soyfoods.

In 1999, as part of the process for approving the coronary heart disease-health claim, the U.S. Food and Drug Administration (FDA) extensively reviewed the scientific literature and concluded that soyfoods are safe.⁸ Most of the concerns being raised today were previously considered by the FDA; however, there is considerably more research since 1999 that has been published. In 2005, the Agency for Healthcare Research and Quality identified only minor problems associated with the intake of large amounts of soy, such as mild gastrointestinal disturbances. Most of the research they evaluated wasn't designed specifically to address safety issues.⁹ Nevertheless, a similar conclusion was reached by Austrian researchers in a recently published meta-analysis, which was undertaken specifically to address the safety of isoflavone supplements.¹⁰ Discussions about the safety of soy continue to appear in the scientific literature and popular media.

The FDA concluded that soyfoods are safe in its review when approving the health claim for soy protein and coronary heart disease.

How Much Soy Protein do Asians and Americans Consume?

There is considerable confusion about the role soy plays in the diets of Asian populations and about how much soy Americans consume. Soy protein is widely used by the food industry and is found in small amounts in an extensive array of foods in the U.S. However, soy protein is added to foods primarily for its functional properties, i.e., to improve shelf stability and texture. Consequently, U.S. daily per capita soy protein intake is only 1-2 g/day, representing about 2 percent of total protein intake.¹¹ Obviously, because soy protein intake is so low, U.S. isoflavone intake is also very low



Traditional Japanese diets include 10 g/day soy protein for 10 percent of total protein needs.

(<2 mg/day). Isoflavone exposure is low not only because of the low soy intake but because the protein used by the food industry is often quite low in isoflavones.

In Japan, the daily intake of soy protein among those consuming a traditional diet is approximately 10 g, which represents slightly more than 10 percent of their total protein intake.¹² Large studies from Shanghai, China, show that men consume about 12-13 g of soy protein per day,¹³ which represents about 15 percent of total protein intake,¹⁴ and that women consume about 9 g/day.¹⁵ Individuals in the upper one-quarter of intake consume about 15-20 g soy protein daily. Ten g of soy protein translates to about 1.5 servings since one serving of a traditional soyfood provides about seven g protein, although some soyfoods can provide considerably more than this amount.

In Japan, about half of soy intake comes from unfermented foods, with four foods – tofu, miso, natto and fried tofu – accounting for about 90 percent of all soy consumption.^{16, 17} In Shanghai, and throughout much of China, most of the soyfoods consumed are unfermented. Soymilk, tofu and processed soy products other than tofu account for about 80 percent of total soy consumption.¹

In conclusion, this intake data indicates that most Americans need to substantially increase their soy intake to match the levels common to the traditional cuisines of many Asian populations. This can be done relatively easily through a variety of fermented and unfermented soyfoods.

Considerations in Evaluating Soy Research

Most scientists can probably agree that there is a legitimate basis for discussion about potential adverse effects of soy consumption, at least in some individuals and under certain circumstances. Some types of in vitro and animal studies have raised concern, although this is hardly surprising given the sheer volume of research conducted. Almost 2,000 soy-related scientific papers are published annually. Unfortunately, sensationalized media stories – and especially online articles lacking editorial oversight – often focus on a tiny minority of studies unrepresentative of the overall scientific literature. Furthermore, they often do not assign proper weight to the type (in vitro, animal, human, clinical, epidemiologic, etc.) of studies being highlighted.

The relevance of in vitro and animal studies to humans is always a matter of debate. Clearly, in vitro conditions cannot duplicate the complexity of living organisms, human or otherwise. Furthermore, by necessity, these studies typically examine the effects of isolated compounds, which may be quite different from the effects seen when these compounds are examined in their natural milieu. The biological impact of one nutrient or non-nutrient in a food can be dependent upon the presence of others.^{18, 19}

Studies in rats and mice, while certainly part of the scientific literature, often have limited value for predicting effects in humans. This is because of the many physiological and anatomical differences between rodents and humans. In the case of soy, there is an additional caveat; most animals, including rodents and non-human primates, metabolize isoflavones very differently than humans.²⁰⁻²⁵ Therefore, one may derive only very limited insight about the possible effects of soyfoods in humans based on the results from rodent studies, as they are fed isoflavone-rich soy protein or mixed isoflavones.

It is also important to recognize that many highly investigated foods and food components have been linked with adverse effects in some studies. This includes foods that are recommended by most nutritionists for their roles as part of a healthy diet. For example, whole grains contain phytate (as do soyfoods), which can decrease mineral absorption.²⁶ Nevertheless, the nutrition community recommends the intake of whole grains because the overwhelming preponderance of evidence indicates that they are nutritionally beneficial.^{27, 28} However, this illustrates the argument that when evaluating any food – including soy – it is necessary to evaluate the totality of the evidence and to carefully consider the strengths and weaknesses of study designs.

Evaluating the Evidence

Hormonal Balance

Isoflavones bind to and transactivate estrogen receptors and can potentially influence steroid hormone synthesis and metabolism via their effects on enzymes involved in a variety of metabolic pathways.^{29, 30} Not surprisingly, there has been considerable investigation of the effects of isoflavone-rich soy products and isoflavone supplements on hormone levels in both men and women. Some of this research was aimed at determining whether decreases in testosterone and estrogen levels might account for the proposed role of soy in reducing risk of prostate and breast cancer, respectively.

The vast majority of studies show no effects on circulating reproductive hormone levels in men or women in response to the intake of soy protein or isoflavones.

However, according to the conclusions of two recently published meta-analyses, the purported chemopreventive effects of soyfoods are unlikely to be related to their effects on blood hormone concentrations. The vast majority of studies have shown no effects on circulating reproductive hormone levels in men^{31, 32} or women³³⁻³⁵ in response to the intake of soy protein or isoflavones. One meta-analysis, which included 32 studies and 36 treatment groups, evaluated the effects of soy products on total and free testosterone in men.³⁶ The other, which included 47 studies, evaluated the effects of soy products on levels of estradiol and other reproductive hormones in pre- and postmenopausal women.³⁷ In addition, a comprehensive review of the clinical research found no evidence that isoflavone exposure affects circulating estrogen levels in men.³⁸ Estrogen is typically thought of as a female hormone, yet men also synthesize estrogen. In fact, estrogen levels in older men are higher than in older women.³⁹

Fertility

Given the large populations of Asian countries that historically have consumed soy, it is ironic that concerns regarding soy intake and fertility have been raised. In many respects, the biological effects of isoflavones first came to the attention of the scientific community in the 1940s. There were breeding problems experienced by female sheep in Western Australia grazing on a type of clover rich in isoflavones.⁴⁰⁻⁴² Furthermore, two decades ago, it was established that isoflavone-rich soy, which was part of the standard diet of cheetahs in North American zoos, was a factor in the decline of fertility in these animals.⁴³ However, problems in the latter arose because felines are poorly able to glucuronidate phenolic compounds, a major step in the bodily elimination of isoflavones – a good example of differences in isoflavone metabolism between animals and humans.⁴⁴⁻⁴⁶ In the case of the sheep, serum levels of equol – a bacterially synthesized metabolite of the soybean isoflavone daidzein – far exceeded anything approaching human levels simply because daily isoflavone intake was estimated to be several grams.⁴⁷ This dwarfs the 40 mg common in the Japanese population.¹²

In women, soyfoods appear to increase the length of the menstrual cycle. However, ovulation is not prevented, but is simply delayed by one day.³⁷ Interestingly, longer cycles are associated with a decreased breast cancer risk.⁴⁸ In men, a small pilot epidemiologic study found that very modest



Fast Facts about Isoflavones

- Isoflavones are one of five chemical classes of anticarcinogens found in soy.
- Soyfoods are the only significant natural dietary source of isoflavones.
- Research shows isoflavones may prevent the onset of osteoporosis and may protect against various forms of cancer.


soy consumption was associated with lower sperm concentration (sperm count was not decreased). However, there were many weaknesses to this study. In fact, much of the decreased sperm concentration occurred because there was an increase in ejaculate volume in men consuming higher amounts of soy, a finding which seems biologically implausible.⁴⁹ In contrast to this one epidemiologic study, all three of the clinical studies conducted show that isoflavones have no effect on sperm concentration or quality.⁴⁹⁻⁵¹ Interestingly, a case report actually noted that isoflavones increased sperm count. Daily isoflavone supplementation for six months in the male partner of an infertile couple with initially low sperm count led to normalization of sperm quality and quantity and allowed the couple to conceive.⁵²

Soy, Isoflavones and Thyroid Function

The first animal studies investigating the effects of soy intake on thyroid function were published 70 years ago.⁵³⁻⁵⁵ Concerns about the anti-thyroid effects of soy are based primarily on in vitro research^{56,57} and studies in rodents administered isolated isoflavones.^{58,59} Although several cases of goiter were attributed to the use of soy infant formula, this problem was eliminated in the mid-1960s with the advent of iodine fortification of the formula.^{53,54,60}

A comprehensive review published in 2006 that included 14 clinical trials found that the totality of the evidence clearly showed that neither soyfoods nor isoflavones adversely affect thyroid function in healthy men or women.⁶¹ Studies published since this review are supportive of the conclusion.⁶²⁻⁶⁶ One of these is a 3-year study that included more than 200 postmenopausal women who were given isoflavone supplements at either 80 mg/day or 120 mg/day (personal communication, Lee Alekel, National Institutes of Health). Another noteworthy study, which also supports the safety of soy, was three years in duration and the intervention product was high-dose genistein (the isoflavone shown in vitro to inhibit the activity of thyroid peroxidase). In addition to measuring thyroid hormones (thyroid stimulating hormone, thyroxine and triiodothyronine) this study also assessed very sensitive indicators of thyroid function, thyroid hormone receptor and retinoid receptor expression from peripheral blood monocytes.⁶⁷

Although soy has no effect on thyroid function in euthyroid individuals, soyfoods may increase the amount of thyroid medication needed by hypothyroid patients. This is not because of an effect on the thyroid but because soy protein may interfere, to an extent, with the absorption of the medication.⁶⁸⁻⁷¹ Soy is not unique in this regard, however, as many herbs,



One serving of a traditional soyfood provides about 20 to 35 mg of isoflavones.

Isoflavone Content of Soyfoods

Soyfood	Serving size	Total (mg) isoflavone/serving
Miso	1 Tbsp	7
Soybeans, Green, Cooked	1/2 cup	50
Soybeans, Black, Cooked	1/2 cup	40
Soybeans, Yellow, Cooked	1/2 cup	78
Soybeans, Roasted, Plain	1/4 cup	78
Soymilk, Plain, Unfortified	1 cup	10
Soymilk, Plain, Fortified	1 cup	43
Soy Flour, Defatted	1/4 cup	42
Soy Flour, Full-Fat	1/4 cup	33
Soy Flour, Low-Fat	1/4 cup	50
Soy Crumbles	1/2 cup	9
Soy Protein Isolate Powder, Plain	1/3 cup	53
Textured Soy Protein, Dry	1/4 cup	33
Tempeh	1/2 cup	53
Tofu	1/2 cup	25

drugs and fiber supplements have similar effects.⁷²⁻⁸⁰ In any event, it is not necessary for thyroid patients (with the exception of infants with congenital hypothyroidism) to avoid soyfoods since thyroid medication is taken on an empty stomach and dosages can easily be adjusted to compensate for any effects of soy. According to a recent position paper from the Pharmacy and Therapeutics Committee of the Lawson Wilkins Pediatric Endocrine Society, it is not necessary to avoid any particular food, or even to avoid taking thyroid hormone during the fasting state. Instead, it is important to maintain consistency in medication administration and dietary habits. As long as the medication is taken in a consistent manner and the amount of soyfoods consumed is relatively constant, soyfoods are not problematic.⁸¹

Finally, a question remains about the effects of soy in individuals whose thyroid function may be compromised, such as subclinical hypothyroid patients and those whose iodine intake is marginal. Due to ethical concerns, a clinical trial evaluating the latter will likely not be conducted. Therefore, in the absence of data, soy consumers should be sure their iodine intake is adequate since there is a theoretical basis for postulating that soy could exacerbate thyroid function when iodine intake is inadequate.⁸² In the U.S., iodine intake is generally quite good, yet subpopulations may not be getting sufficient amounts of this mineral.⁸³ In any event, with an individual whose iodine intake is suboptimal, the appropriate recommendation is to increase iodine intake instead of avoid soyfoods.



The American Cancer Society states that breast cancer patients can safely consume up to 3 servings of traditional soyfoods daily.

Only recently has information on the effects of soy intake on thyroid function in subclinical hypothyroid patients become available. Estimates vary, but approximately 5 percent of the general adult population, and a higher percentage among individuals over the age of 60, have subclinical hypothyroidism.⁸⁴ With time, a certain percentage (~2-6 percent/year) of these patients, who have normal triiodothyronine and thyroxine levels but elevated levels of thyroid stimulating hormone, will spontaneously progress to overt hypothyroidism.⁸⁵ In a crossover study,

Human data indicate that isoflavones, regardless of the source, do not exert harmful effects on breast tissue.

60 middle-aged, overweight British patients (52 females) consumed, in random order for eight weeks, 30 g isolated soy protein (ISP) containing 2 or 16 mg isoflavones separated by an eight week crossover. During the entire 6-month study period, six of the subjects (10 percent) consuming the higher-isoflavone-ISP progressed to overt hypothyroidism, whereas none did in the low isoflavone group. As a result, it was estimated that exposure to 16 mg/day isoflavones increased the likelihood of converting to overt hypothyroidism approximately 3.6-fold.

These results are unexpected given the relatively small isoflavone intake of the subjects. The progression of subclinical to overt hypothyroidism among Japanese patients is not elevated,⁸⁶ nor does Japan have higher rates of hypothyroidism.⁸⁷ Nevertheless, the results of the British study can't be dismissed. It is important to note that, in the subjects overall (including those who became hypothyroid), there were dramatic reductions in systolic and diastolic blood pressure, insulin resistance and inflammation (as assessed by C-reactive protein). Thus, in theory, isoflavones markedly reduced risk of cardiovascular disease and diabetes in people with subclinical hypothyroid function. However, additional research is required before firm conclusions about the effects of soyfoods on thyroid function in these patients can be made.

Soyfoods and Breast Cancer Risk

The estrogen-like effects of isoflavones form the theoretical basis for concern that soyfoods are contraindicated for women who are at increased risk of breast cancer or estrogen-sensitive tumors.⁸⁸⁻⁹² Isoflavones bind to estrogen receptors, stimulate the growth of human estrogen receptor positive (ER+) breast cancer cells in vitro, and in certain types of experimental rodent models, stimulate the growth of existing estrogen-responsive mammary tumors.^{93,94} However, not all rodent models show that soy or isoflavones stimulate the growth of existing mammary tumors,⁹⁵⁻⁹⁷ and even in rodent models that do show this, minimally processed soyfoods do not have this effect.⁹⁸ More importantly, the human data indicate that isoflavones, regardless of the source, do not exert harmful effects on breast tissue.

In none of the five clinical trials in which researchers took breast tissue biopsies before and after exposure to isoflavones – three involving postmenopausal, one premenopausal, and one with both pre- and postmenopausal women – were effects on cell proliferation noted.^{33, 99-102} Increased cell proliferation is generally regarded as a risk factor for cancer. Isoflavone exposure also has no effect on breast tissue density (increased density is a marker of cancer risk).¹⁰³⁻¹⁰⁶ In contrast to the lack of effects of isoflavones, estrogen plus progestin hormone therapy (which increases breast cancer risk)¹⁰⁷ increases breast tissue density and breast cell proliferation.^{108, 109}

In addition, four recently published prospective epidemiologic studies, two from China^{110, 111} and two from the United States^{112, 113} show that in contrast to the animal data, post-diagnosis soy intake improves the prognosis in women who have had breast cancer. Details of the largest Chinese study and largest U.S. study are presented.

Data from the Shanghai Breast Cancer Survival Study (SBCSS), a population-based cohort study of breast cancer survivors, were analyzed to investigate the effect of soy intake on breast cancer prognosis.¹¹⁰ During the median follow-up period of approximately 3.9 years, the hazard ratios associated with the fourth soy protein intake quartile were 0.71 for total mortality and 0.68 for recurrence with both findings being statistically significant. In fact, in this study, high soy intake was as protective as tamoxifen. In an editorial accompanying this article, researchers from the National Cancer Institute and Fred Hutchinson Research Center in Seattle concluded that, “Patients with breast cancer can be assured that enjoying a soy latte or indulging in pad thai with tofu causes no harm and, when consumed in plentiful amounts, may reduce risk of disease recurrence.”¹¹⁴

The U.S. study involved 2,736 breast cancer survivors diagnosed between 1991 and 2000 with early stage breast cancer who were participants in the Women’s Healthy Eating and Living study.¹¹³ During the median 7.3 year follow-up period, there were 448 new breast cancer events and 271 deaths. The results showed that, as isoflavone intake increased, risk of death decreased. Women in the highest isoflavone intake category (cutoff, >16.3 mg/day; median 26.7 mg/day) had a 54 percent reduction in risk of death (p for trend=0.02). The benefits of isoflavone intake were most evident in users of tamoxifen. Interestingly, in one of the Chinese studies, soy intake was associated with an improved efficacy of the aromatase inhibitor, anastrozole.¹¹¹ The tamoxifen and anastrozole findings are noteworthy not only because of the possible implications for breast cancer patients on treatment, but because in the mouse model that has raised concerns about the effects of isoflavones on the breast, isoflavones were found to inhibit the efficacy of these drugs.^{115, 116} Thus, in essentially all respects, the human and rodent data differ in that the latter raise concerns whereas the former are supportive of safety and potential benefit.

In four recently published studies, results show that post-diagnosis soy intake improves the prognosis in women who have had breast cancer.

Finally, the clinical and epidemiologic findings described above are certainly consistent with the position of the American Cancer Society that breast cancer patients can safely consume up to three servings of traditional soyfoods daily.¹¹⁷ A recent commentary concluded that the current default position of oncologists advising their breast cancer patients to limit or avoid soy intake is no longer justified.¹¹⁸ This is because the clinical studies showed isoflavones not adversely affecting breast tissue and recent epidemiologic studies showed soy consumption improves breast cancer prognosis. However, the commentary also noted that the data does not justify actively recommending soy specifically for the purpose of improving prognosis. Rather, a position in between these two extremes was deemed most defensible. That is, to agree to allow women consuming soy who develop breast cancer to continue doing so and to allow breast cancer patients who want to begin consuming soy, for whatever reason, to do so. Nevertheless, breast cancer patients should discuss any dietary changes with their primary healthcare provider.

Effects of Soy on Mineral Status

Soyfoods are frequently used in place of animal foods, many of which are good sources of iron, zinc and, in the case of dairy foods, calcium. Relatively little red meat is needed to meet daily iron and zinc requirements, thus questions about the effects of soy on the status of these two minerals pertains mostly to those eating a predominately plant-based diet.¹¹⁹

New research indicates that iron absorption from soy may be much higher than previously thought because the majority of iron in soy is in the form of ferritin, which recent research has shown is highly bioavailable.

As noted previously, soybeans, like other legumes and whole grains, are high in phytate,¹²⁰ which reduces the absorption of some minerals, including zinc and iron.¹²¹ Zinc absorption from soyfoods is only modestly lower than that from other sources. However, because soybeans contain relatively little zinc, unfortified soyfoods are not particularly good sources of this mineral.¹²²⁻¹²⁵ Zinc status is difficult to assess^{126, 127} and those consuming a plant-based diet are advised to identify good plant sources of zinc in their diet or to take a zinc supplement.¹²⁸⁻¹³²

In contrast to zinc, soyfoods are relatively high in iron.¹³³ Until recently, it was believed that the iron in essentially all plant foods, including soyfoods, was poorly absorbed. However, new research utilizing improved methodology indicates that iron absorption from soy may be much higher than previously thought because the majority of iron in soy is in the form of ferritin. Although there is debate about the bioavailability of ferritin iron,



two important clinical studies, in which subjects were fed either soyfoods or soybean ferritin, show it to be highly bioavailable.^{134, 135} In support of these observations are the results from a study designed specifically to examine the effect of soyfoods on mineral status. In this study, young premenopausal women consumed either 2-3 servings of soyfoods daily or non-soyfoods matched for type of food—such as hamburgers in place of soy burgers or cow's milk in place of soymilk. Results showed there were no statistically significant effects of soy on urinary and serum zinc, serum hemoglobin and iron, or transferrin saturation (see reference for a description of this study).⁵¹

While mineral absorption may be very slightly improved with fermentation and may give rise to other potentially beneficial compounds, there is little evidence that these foods are superior to unfermented ones.

In addition to phytate, soybeans are also high in oxalate, another compound that binds calcium and reduces its absorption.¹³⁶ Oxalate is one reason that spinach, despite being high in calcium, is not a good source of this mineral. However, despite the presence of both phytate and oxalate, calcium absorption from soybeans is surprisingly good.¹³⁷ This is also true for calcium-set tofu¹³⁸ and calcium-fortified soymilk.^{139, 140} In fact, the absorption of calcium from these foods is comparable to the absorption of calcium from cow's milk. Bioavailability of calcium from calcium-fortified products, such as soymilk, depends to some extent on the type of supplemental calcium used.¹³⁸ When calcium carbonate is used as the fortificant in soymilk, absorption is similar to that seen with cow's milk.¹³⁹ In contrast, calcium absorption from soymilk fortified with tricalcium phosphate is about 25 percent lower than from cow's milk.¹³⁹ Yet, as the high amounts of tricalcium phosphate are added, the amount of calcium available to the body from both types of calcium-fortified soymilk is similar to that from cow's milk.¹³⁹

Finally, questions have been raised about the solubility of calcium in soymilk. Some research indicates that, even with vigorous shaking, the calcium in soymilk comes out of the solution.¹⁴² While some sedimentation may occur in certain soymilk, this sediment is re-suspended with mild shaking for the majority of soymilk purchased in the United States.



Allergies

Soy protein can cause allergic reactions in sensitive individuals, as is the case for essentially all food proteins. Soy protein is one of the eight foods responsible for approximately 90 percent of all food-induced allergic reactions in the United States.¹⁴³ However, these foods are not equally allergenic, and allergy to soy protein is relatively rare.^{144, 145} A recent nationally representative telephone survey found that only approximately one out of 2,500 adults reported having a doctor-diagnosed allergy to soy protein.¹⁴⁵ The results of this survey indicate that cow's milk allergy (CMA) is about 40 times more common than soy allergy. The prevalence of soy allergy is undoubtedly higher in children than adults, as children are more likely to have food allergies in general. However, by age 10, an estimated 70 percent of children will outgrow their soy allergies.¹⁴⁶ Consequently, it is estimated that, by that age, only approximately one out of 1,000 children is allergic to soy.

According to the American Academy of Pediatrics (AAP), extensively hydrolyzed protein formula should be considered as the first alternative for infants with documented CMA (especially for IgE-mediated reactions), because 10-14 percent of these infants will also have a soy protein allergy.¹⁴⁷ However, recently conducted U.K. research found that 60 percent of all infants with CMA were initially treated with soy, and of those, only 9 percent of patients remained symptomatic.¹⁴⁸ In contrast, of the 18 percent of patients treated with extensively hydrolyzed formula, 29 percent remained symptomatic. The results from a small retrospective study from Portugal, which evaluated children with persistent CMA, also suggest that soy formula may have advantages over hydrolyzed formulas.¹⁴⁹

Recent research shows that only about one out of 2,500 American adults are allergic to soy protein.

Soy Infant Formula


Soy infant formula (SF) has been in use for more than 50 years. Currently, it accounts for about 13 percent of all dollars spent on infant formula in the U.S.. An estimated 20 million infants have used SF over the past 40 years. Soy formula produces normal growth and development; nevertheless, SF use has become controversial because of its high isoflavone content. In 2009, the U.S. National Toxicology Program (NTP) concluded there was minimal concern about the safety of SF. However, in response to this conclusion, the AAP submitted a letter to the NTP, which is now part of the public record, stating that in their view, there was negligible concern about the safety of SF. The five levels of concern are negligible, minimal, some, concern and serious concern. Over the next few years, considerable insight to the health effects of SF will be gained as a result of research underway at the Arkansas Children's Nutrition Center at the University of Arkansas for Medical Sciences. At this center, the health status of infants fed breast milk, cow's milk formula and SF is being compared. Thus far, findings indicate that all health parameters assessed in infants fed SF are well within the normal range.¹⁵⁰⁻¹⁵³

Soyfood Processing

Tofu and miso are the most commonly consumed soyfoods in Japan and China, whereas, in the U.S., many people choose more processed forms of soy such as meat analogs and energy bars.¹⁵⁴ Numerous human studies demonstrate that processed soy products provide very high quality soy protein.^{155, 156}

Depending on processing methods, however, the isoflavone content of these foods can be markedly reduced.¹⁵⁷ The isoflavone content of a large number of soy-containing foods can be found in an online database created by Iowa State University and the United States Department of Agriculture at: <http://www.nal.usda.gov/fnic/foodcomp/Data/isoflav/isoflav.html>.

Many traditional soyfoods such as miso, tempeh and natto undergo fermentation. While mineral absorption may be very slightly improved with fermentation and may give rise to other potentially beneficial compounds, there is little evidence that these foods are superior to unfermented ones. In fact, several epidemiologic studies show protective effects of non-fermented soyfoods.^{158, 159} Non-fermented soyfoods have been consumed in Japan¹⁶⁰ and China¹⁶¹ for at least 500 years and 1,000 years, respectively. In Japan, where many fermented foods are popular, at least half of the total soy consumed comes from foods that are not fermented.^{16, 17} In China, most soy is consumed in non-fermented form.¹



Summary and Conclusions

When evaluating the safety of soyfoods, it is imperative to consider the totality of the scientific research and to place weight on studies according to their experimental design. The research overall indicates that soyfoods can be safely incorporated into the diets of essentially all healthy individuals with the exception of those allergic to soy protein. Nevertheless, because all foods have the potential to cause undesirable effects in some individuals, people with specific health concerns should consult their healthcare provider regarding unique nutritional needs.

References

- Zhang X, Shu XO, Gao YT, Yang G, Li Q, Li H, Jin F, Zheng W. Soy food consumption is associated with lower risk of coronary heart disease in Chinese women. *J Nutr*. 2003; 133: 2874-8.
- Kokubo Y, Iso H, Ishihara J, Okada K, Inoue M, Tsugane S. Association of dietary intake of soy, beans, and isoflavones with risk of cerebral and myocardial infarctions in Japanese populations: the Japan Public Health Center-based (JPHC) study cohort I. *Circulation*. 2007; 116: 2553-62.
- Messina M, Lane B. Soy protein, soybean isoflavones, and coronary heart disease risk: Where do we stand? *Future Lipidology*. 2007; 2: 55-74.
- Ma DF, Qin LQ, Wang PY, Katoh R. Soy isoflavone intake inhibits bone resorption and stimulates bone formation in menopausal women: meta-analysis of randomized controlled trials. *Eur J Clin Nutr*. 2008; 62:155-61.
- Marini H, Minutoli L, Polito F, Bitto A, Altavilla D, Atteritano M, Gaudio A, Mazzaferro S, Frisina A, et al. Effects of the phytoestrogen genistein on bone metabolism in osteopenic postmenopausal women: a randomized trial. *Ann Intern Med*. 2007; 146: 639-47.
- Koh WP, Wu AH, Wang R, Ang LW, Heng D, Yuan JM, Yu MC. Gender-specific associations between soy and risk of hip fracture in the Singapore Chinese Health Study. *Am J Epidemiol*. 2009; 170: 901-9.
- Shu XO, Jin F, Dai Q, Wen W, Potter JD, Kushi LH, Ruan Z, Gao YT, Zheng W. Soyfood intake during adolescence and subsequent risk of breast cancer among Chinese women. *Cancer Epidemiol Biomarkers Prev*. 2001; 10: 483-8.
- Food Labeling: Health Claims; Soy Protein and Coronary Heart Disease. Federal Register: (Volume 64, Number 206), 1999:57699-57733.
- Balk E, Chung M, Chew P, Ip S, Raman G, Kuplenick B, Tatsioni A, Sun Y, Wolk B, et al. Effects of soy on health outcomes. Evidence report/technology assessment No. 126 (prepared by Tufts-New England Medical Center Evidence-based Practice Center under Contract No. 290-02-0022.) AHRQ Publication No. 05-E024-2. Rockville, MD Agency for Healthcare Research and Quality, July 2005.
- Tempfer CB, Froshe G, Heinze G, Bentz EK, Hefler LA, Huber JC. Side effects of phytoestrogens: a meta-analysis of randomized trials. *Am J Med*. 2009; 122: 939-46 e9.
- Smit E, Nieto FJ, Crespo CJ, Mitchell P. Estimates of animal and plant protein intake in US adults: results from the Third National Health and Nutrition Examination Survey, 1988-1991. *J Am Diet Assoc*. 1999; 99: 813-20.
- Messina M, Nagata C, Wu AH. Estimated Asian adult soy protein and isoflavone intakes. *Nutr Cancer*. 2006; 55: 1-12.
- Lee SA, Wen W, Xiang YB, Barnes S, Liu D, Cai Q, Zheng W, Shu XO. Assessment of Dietary Isoflavone Intake among Middle-Aged Chinese Men. *J Nutr*. 2007; 137: 1011-1016.
- Villegas R, Yang G, Liu D, Xiang YB, Cai H, Zheng W, Shu XO. Validity and reproducibility of the food-frequency questionnaire used in the Shanghai men's health study. *Br J Nutr*. 2007; 97: 993-1000.
- Yang G, Shu XO, Jin F, Zhang X, Li HL, Li Q, Gao YT, Zheng W. Longitudinal study of soy food intake and blood pressure among middle-aged and elderly Chinese women. *Am J Clin Nutr*. 2005; 81: 1012-7.
- Wakai K, Egami I, Kato K, Kawamura T, Tamakoshi A, Lin Y, Nakayama T, Wada M, Ohno Y. Dietary intake and sources of isoflavones among Japanese. *Nutr Cancer*. 1999; 33: 139-45.
- Somekawa Y, Chiguchi M, Ishibashi T, Aso T. Soy intake related to menopausal symptoms, serum lipids, and bone mineral density in postmenopausal Japanese women. *Obstet Gynecol*. 2001; 97: 109-115.
- Rozen P, Lubin F, Papo N, Knaani J, Farbstein H, Farbstein M, Zajicek G. Calcium supplements interact significantly with long-term diet while suppressing rectal epithelial proliferation of adenoma patients. *Cancer*. 2001; 91: 833-40.
- Bolca S, Wyns C, Possesiers S, Deypyere H, De Keukelleire D, Bracke M, Verstraete W, Heyerick A. Cosupplementation of isoflavones, Prenylflavonoids, and Lignans Alters Human Exposure to Phytoestrogen-Derived 17(beta)-Estradiol Equivalents. *J Nutr*. 2009; 139: 2293-300.
- Wisniewski AB, Klein SL, Lakhshmanan Y, Gearhart JP. Exposure to genistein during gestation and lactation demasculinizes the reproductive system in rats. *J Urol*. 2003; 169: 1582-6.
- Fielden MR, Samy SM, Chou KC, Zacharewski TR. Effect of human dietary exposure levels of genistein during gestation and lactation on long-term reproductive development and sperm quality in mice. *Food Chem Toxicol*. 2003; 41: 447-54.
- Ojeda SR, Andrews WW, Advis JP, White SS. Recent advances in the endocrinology of puberty. *Endocr Rev*. 1980; 1: 228-57.
- Robinson JD, Judd HL, Young PE, Jones OW, Yen SS. Amniotic fluid androgens and estrogens in midgestation. *J Clin Endocrinol Metab*. 1977; 45: 755-61.
- Gu L, House SE, Prior RL, Fang N, Ronis MJ, Clarkson TB, Wilson ME, Badger TM. Metabolic phenotype of isoflavones differ among female rats, pigs, monkeys, and women. *J Nutr*. 2006; 136: 1215-21.
- Setchell KD, Brown NM, Zhao X, Lindley SL, Heubi JE, King EC, Messina MJ. Soy isoflavone phase II metabolism differs between rodents and humans: implications for the effect on breast cancer risk. *Am J Clin Nutr*. 2011; 94: 1284-94.
- Larsson M, Rossander-Hulthen L, Sandstrom B, Sandberg AS. Improved zinc and iron absorption from breakfast meals containing milled oats with reduced phytate content. *Br J Nutr*. 1996; 76: 677-88.
- Harris KA, Kris-Etherton PM. Effects of whole grains on coronary heart disease risk. *Curr Atheroscler Rep*. 2010; 12: 368-76.
- Slavin J. Whole grains and human health. *Nutr Res Rev*. 2004; 17: 99-110.
- Rice S, Mason HD, Whitehead SA. Phytoestrogens and their low dose combinations inhibit mRNA expression and activity of aromatase in human granulosa-luteal cells. *J Steroid Biochem Mol Biol*. 2006; 101: 216-25.
- Lacey M, Boiday J, Fonseka SM, Ullah AI, Whitehead SA. Dose-response effects of phytoestrogens on the activity and expression of 3beta-hydroxysteroid dehydrogenase and aromatase in human granulosa-luteal cells. *J Steroid Biochem Mol Biol*. 2005; 96: 279-86.
- Dillingham BL, McVeigh BL, Lampe JW, Duncan AM. Soy protein isolates of varying isoflavone content exert minor effects on serum reproductive hormones in healthy young men. *J Nutr*. 2005; 135: 584-91.
- Hamilton-Reeves JM, Rebello SA, Thomas W, Slaton JW, Kurzer MS. Isoflavone-rich soy protein isolate suppresses androgen receptor expression without altering estrogen receptor-(beta) expression or serum hormonal profiles in men at high risk of prostate cancer. *J Nutr*. 2007; 137: 1769-1775.
- Cheng G, Wilczek B, Warner M, Gustafsson JA, Landgren BM. Isoflavone treatment for acute menopausal symptoms. *Menopause*. 2007; 14: 468-73.
- Brown BD, Thomas W, Hutchins A, Martini MC, Slavin JL. Types of dietary fat and soy minimally affect hormones and biomarkers associated with breast cancer risk in premenopausal women. *Nutr Cancer*. 2002; 43: 22-30.
- Duncan AM, Underhill KE, Xu X, Lavalleur J, Phipps WR, Kurzer MS. Modest hormonal effects of soy isoflavones in postmenopausal women. *J Clin Endocrinol Metab*. 1999; 84: 3479-84.
- Hamilton-Reeves JM, Vazquez G, Duval SJ, Phipps WR, Kurzer MS, Messina MJ. Clinical studies show no effects of soy protein or isoflavones on reproductive hormones in men: results of a meta-analysis. *Fertil Steril*. 2010; 94: 997-1007.
- Hooper L, Ryder J, Kurzer MS, Lampe JW, Messina MJ, Phipps WR, Cassidy A. Effects of soy protein and isoflavones on circulating hormone concentrations in pre- and post-menopausal women: a systematic review and meta-analysis. *Hum Reprod Update*. 2009; 15: 423-40.
- Messina M. Soybean isoflavone exposure does not have feminizing effects on men: a critical examination of the clinical evidence. *Fertil Steril*. 2010; 93: 2095-104.
- Greendale GA, Edelstein S, Barrett-Connor E. Endogenous sex steroids and bone mineral density in older women and men: the Rancho Bernardo Study. *J Bone Miner Res*. 1997; 12: 1833-43.
- Bennetts HW, Underwood EJ, Shier FL. A specific breeding problem of sheep on subtropical clover pastures in Western Australia. *Aust J Agric Res*. 1946; 22: 131-138.
- Bradbury RB, White DR. Estrogen and related substances in plants. In: Harris RS, Marrian GF, Thimann KV, eds. *Vitam Horm*. New York: Academic Press, 1954:207-230.
- Lundh TJ-O, Petterson HL, Martinsson KA. Comparative levels of free and conjugated plant estrogens in blood plasma of sheep and cattle fed estrogenic silage. *J Agric Food Chem*. 1990; 38: 1530-1534.
- Setchell KD, Gosselin SJ, Welsh MB, Johnston JO, Balistrieri WF, Kramer LW, Dresser BL, Tarr MJ. Dietary estrogens--a probable cause of infertility and liver disease in captive cheetahs. *Gastroenterology*. 1987; 93: 225-33.
- Setchell KD, Brown NM, Lydeking-Olsen E. The clinical importance of the metabolite equol--a clue to the effectiveness of soy and its isoflavones. *J Nutr*. 2002; 132: 3577-84.
- Rowland I, Faughnan M, Hoey L, Wahala K, Williamson G, Cassidy A. Bioavailability of phyto-estrogens. *Br J Nutr*. 2003; 89 Suppl 1: S45-58.
- Rowland IR, Wiseman H, Sanders TA, Adlercreutz H, Bowey EA. Interindividual variation in metabolism of soy isoflavones and lignans: influence of habitual diet on equol production by the gut microflora. *Nutr Cancer*. 2000; 36: 27-32.
- Urpi-Sarda M, Morand C, Besson C, Kraft G, Viala D, Scalbert A, Besle JM, Manach C. Tissue distribution of isoflavones in ewes after consumption of red clover silage. *Arch Biochem Biophys*. 2008; 476: 205-10.
- Kurzer MS. Hormonal effects of soy in premenopausal women and men. *J Nutr*. 2002; 132: 570S-3S.
- Mitchell JH, Cawood E, Kinniburgh D, Provan A, Collins AR, Irvine DS. Effect of a phytoestrogen food supplement on reproductive health in normal males. *Clin Sci (Lond)*. 2001; 100: 613-8.
- Beaton LK, McVeigh BL, Dillingham BL, Lampe JW, Duncan AM. Soy protein isolates of varying isoflavone content do not adversely affect semen quality in healthy young men. *Fertil Steril*. 2010; 94: 1717-22.
- Messina M, Watanabe S, Setchell KD. Report on the 8th International Symposium on the Role of Soy in Health Promotion and Chronic Disease Prevention and Treatment. *J Nutr*. 2009; 139: 796S-802S.
- Casini ML, Gerli S, Unfer V. An infertile couple suffering from oligospermia by partial sperm maturation arrest: can phytoestrogens play a therapeutic role? A case report study. *Gynecol Endocrinol*. 2006; 22: 399-401.
- Van Wyk JJ, Arnold MB, Wynn J, Pepper F. The effects of a soybean product on thyroid function in humans. *Pediatrics*. 1959; 24: 752-760.
- Shepard TH, Gordon EP, Kirschch JF, McLean CM. Soybean goiter. *New Engl J Med*. 1960; 262: 1099-1103.
- Hydovitz JD. Occurrence of goiter in an infant on a soy diet. *New England J Medicine*. 1960; 262: 351-353.
- Divi RL, Doerge DR. Inhibition of thyroid peroxidase by dietary flavonoids. *Chem Res Toxicol*. 1996; 9: 16-23.
- Divi RL, Chang HK, Doerge DR. Anti-thyroid isoflavones from soybean: isolation, characterization, and mechanisms of action. *Biochem Pharmacol*. 1997; 54: 1087-96.
- Chang HC, Doerge DR. Dietary genistein inactivates rat thyroid peroxidase in vivo without an apparent hypothyroid effect. *Toxicol Appl Pharmacol*. 2000; 168: 244-52.

59. Chang HC, Churchwell MI, Delclos KB, Newbold RR, Doerge DR. Mass spectrometric determination of genistein tissue distribution in diet-exposed Sprague-Dawley rats. *J Nutr*. 2000; 130: 1963-70.
60. Pinchera A, MacGillivray H, Crawford JD, Freeman AG. Thyroid refractiveness in an athyreotic cretin fed soybean formula. *N Engl J Med*. 1965; 273: 83-87.
61. Messina M, Redmond G. Effects of soy protein and soybean isoflavones on thyroid function in healthy adults and hypothyroid patients: a review of the relevant literature. *Thyroid*. 2006; 16: 249-58.
62. Ryan-Borchers T, Boon C, Park JS, McGuire M, Fournier L, Beerman K. Effects of dietary and supplemental forms of isoflavones on thyroid function in healthy postmenopausal women. *Topics Clinical Nutr*. 2008; 23: 13-22.
63. Romaldi D, Costantini B, Campagna G, Lanzoni A, Guido M. Is there a role for soy isoflavones in the therapeutic approach to polycystic ovary syndrome? Results from a pilot study. *Fertil Steril*. 2008; 90: 1826-33.
64. Nahas EA, Nahas-Neto J, Orsatti FL, Carvalho EP, Oliveira ML, Dias R. Efficacy and safety of a soy isoflavone extract in postmenopausal women: a randomized, double-blind, and placebo-controlled study. *Maturitas*. 2007; 58: 249-58.
65. Khoadrari L, Ricciotti HA, Li L, Pan W, Schickel M, Zhou J, Blackburn GL. Daidzein-rich isoflavone aglycones are potentially effective in reducing hot flashes in menopausal women. *Menopause*. 2008; 15: 125-32.
66. Zhou Y, Alekel DL, Dixon PM, Messina M, Reddy MB. The effect of soy food intake on mineral status in premenopausal women. *J Womens Health (Larchmt)*. 2011; 20: 771-80.
67. Bitto A, Polito F, Atteritano M, Altavilla D, Mazzaferro S, Marini H, Adamo EB, D'Anna R, Granese R, et al. Genistein aglycone does not affect thyroid function: results from a three-year, randomized, double-blind, placebo-controlled trial. *J Clin Endocrinol Metab*. 2010; 95: 3067-72.
68. Doerge DR, Sheehan DM. Goitrogenic and estrogenic activity of soy isoflavones. *Environ Health Perspect*. 2002; 110 Suppl 3: 349-53.
69. Fitzpatrick M. Soy formulas and the effects of isoflavones on the thyroid. *N Z Med J*. 2000; 113: 24-6.
70. Bell DS, Ovalle F. Use of soy protein supplement and resultant need for increased dose of levothyroxine. *Endocr Pract*. 2001; 7: 193-4.
71. Conrad SC, Chiu H, Silverman BL. Soy formula complicates management of congenital hypothyroidism. *Arch Dis Child*. 2004; 89: 37-40.
72. Liel Y, Harman-Boehm I, Shany S. Evidence for a clinically important adverse effect of fiber-enriched diet on the bioavailability of levothyroxine in adult hypothyroid patients. *J Clin Endocrinol Metab*. 1996; 81: 857-9.
73. Chiu AC, Sherman SI. Effects of pharmacological fiber supplements on levothyroxine absorption. *Thyroid*. 1998; 8: 667-71.
74. Shakir KM, Chute JP, April BS, Lazarus AA. Ferrous sulfate-induced increase in requirement for thyroxine in a patient with primary hypothyroidism. *South Med J*. 1997; 90: 637-9.
75. Liel Y, Sperber AD, Shany S. Nonspecific intestinal adsorption of levothyroxine by aluminum hydroxide. *Am J Med*. 1994; 97: 363-5.
76. Sperber AD, Liel Y. Evidence for interference with the intestinal absorption of levothyroxine sodium by aluminum hydroxide. *Arch Intern Med*. 1992; 152: 183-4.
77. Sherman SI, Tielsen ET, Ladenson PW. Sucralfate causes malabsorption of L-thyroxine. *Am J Med*. 1994; 96: 531-5.
78. Siraj ES, Gupta MK, Reddy SS. Raloxifene causing malabsorption of levothyroxine. *Arch Intern Med*. 2003; 163: 1367-70.
79. Rosenberg R. Malabsorption of thyroid hormone with cholestyramine administration. *Conn Med*. 1994; 58: 109.
80. Harman SM, Seifert CF. Levothyroxine-cholestyramine interaction reemphasized. *Ann Intern Med*. 1991; 115: 658-9.
81. Zeitler P, Solberg P. Food and levothyroxine administration in infants and children. *J Pediatr*. 2010; 157: 13-14 e1.
82. Doerge D, Chang H. Inactivation of thyroid peroxidase by soy isoflavones, in vitro and in vivo. *J Chromatogr B Analyt Technol Biomed Life Sci*. 2002; 777: 269-279.
83. Caldwell KL, Miller GA, Wang RY, Jain RB, Jones RL. Iodine status of the U.S. population, National Health and Nutrition Examination Survey 2003-2004. *Thyroid*. 2008; 18: 1207-14.
84. Villar HC, Sacaonato H, Valente O, Atallah AN. Thyroid hormone replacement for subclinical hypothyroidism. *Cochrane Database Syst Rev*. 2007; CD003419.
85. Aoki Y, Belin RM, Clickner R, Jeffries R, Phillips L, Mahaffey KR. Serum TSH and total T4 in the United States population and their association with participant characteristics: National Health and Nutrition Examination Survey (NHANES 1997-2002). *Thyroid*. 2007; 17: 1211-23.
86. Imaizumi M, Sera N, Ueki I, Horie I, Ando T, Usa T, Ichimaru S, Nakashima E, Hida A, et al. Risk for progression to overt hypothyroidism in an elderly Japanese population with subclinical hypothyroidism. *Thyroid*. 2011; 21: 1177-82.
87. Kasagi K, Takahashi N, Inoue G, Honda T, Kawachi Y, Izumi Y. Thyroid function in Japanese adults as assessed by a general health checkup system in relation with thyroid-related antibodies and other clinical parameters. *Thyroid*. 2009; 19: 937-44.
88. Bouker KB, Hilakivi-Clarke L. Genistein: Does it Prevent or Promote Breast Cancer? *Environ Health Perspect*. 2000; 108: 701-708.
89. Messina MJ, Loprinzi CL. Soy for breast cancer survivors: a critical review of the literature. *J Nutr*. 2001; 131: 3095S-108S.
90. Affenio SG, Kerstetter J. Position of the American Dietetic Association and Dietitians of Canada: women's health and nutrition. *J Am Diet Assoc*. 1999; 99: 738-51.
91. American College of Obstetricians and Gynecologists. Use of botanicals for management of menopausal symptoms. *ACOG Practice Bulletin*. 2001; 28: 1-11.
92. American Cancer Society Workshop on Nutrition and Physical Activity for Cancer Survivors. Nutrition during and after cancer treatment: a guide for informed choices by cancer survivors. *CA Cancer J Clin*. 2001; 51: 153-187.
93. Ju YH, Allred CD, Allred KF, Karko KL, Doerge DR, Helferich WG. Physiological Concentrations of Dietary Genistein Dose-Dependently Stimulate Growth of Estrogen-Dependent Human Breast Cancer (MCF-7) Tumors Implanted in Athymic Nude Mice. *J Nutr*. 2001; 131: 2957-2962.
94. Allred CD, Ju YH, Allred KF, Chang J, Helferich WG. Dietary genistein stimulates growth of estrogen-dependent breast cancer tumors similar to that observed with genistein. *Carcinogenesis*. 2001; 22: 1667-73.
95. Kang X, Jin S, Zhang Q. Antitumor and antiangiogenic activity of soy phytoestrogen on 7,12-dimethylbenz[alpha]anthracene-induced mammary tumors following ovariectomy in Sprague-Dawley rats. *J Food Sci*. 2009; 74: H237-42.
96. Mishra R, Bhaduria S, Murthy PK, Murthy PS. Glycine soya diet synergistically enhances the suppressive effect of tamoxifen and inhibits tamoxifen-promoted hepatocarcinogenesis in 7,12-dimethylbenz[alpha]anthracene-induced rat mammary tumor model. *Food Chem Toxicol*. 2010; 49: 434-40.
97. Onoda A, Ueno T, Uchiyama S, Hayashi SI, Kato K, Wake N. Effects of S-equol and natural S-equol supplement (SES-OH) on the growth of MCF-7 in vitro and as tumors implanted into ovariectomized athymic mice. *Food Chem Toxicol*. 2011; 49: 279-84.
98. Allred CD, Allred KF, Ju YH, Goepfinger TS, Doerge DR, Helferich WG. Soy processing influences growth of estrogen-dependent breast cancer tumors. *Carcinogenesis*. 2004; 25: 1649-57.
99. Sartipouour MR, Rao JY, Apple S, Wu D, Henning S, Wang H, Elashoff R, Rubio R, Heber D, et al. A pilot clinical study of short-term isoflavone supplements in breast cancer patients. *Nutr Cancer*. 2004; 49: 59-65.
100. Palomares MR, Hopper L, Goldstein L, Lehman CD, Storer BE, Gralow JR. Effect of soy isoflavones on breast proliferation in postmenopausal breast cancer survivors. *Breast Cancer Res Treatment*. 2004; 88 (Suppl 1): 4002.
101. Hargreaves DF, Patten CS, Harding C, Shaw LE, Morton MS, Roberts SA, Howell A, Bundred NJ. Two-week dietary soy supplementation has an estrogenic effect on normal premenopausal breast. *J Clin Endocrinol Metab*. 1999; 84: 4017-24.
102. Khan SA, Chatterton RT, Michel N, et al. Soy isoflavone supplementation for breast cancer risk reduction: A randomized phase II trial. *Cancer Prev Res (Phila)*. 2012; 5: 309-19.
103. Maskarinec G, Williams AE, Carlin L. Mammographic densities in a one-year isoflavone intervention. *Eur J Cancer Prev*. 2003; 12: 165-9.
104. Maskarinec G, Franke AA, Williams AE, Hebsi S, Oshiro C, Murphy S, Stanczyk FZ. Effects of a 2-year randomized soy intervention on sex hormone levels in premenopausal women. *Cancer Epidemiol Biomarkers Prev*. 2004; 13: 1736-44.
105. Atkinson C, Warren RM, Sala E, Dowsett M, Dunning AM, Healey CS, Runswick S, Day NE, Bingham SA. Red-clover-derived isoflavones and mammographic breast density: a double-blind, randomized, placebo-controlled trial. *Breast Cancer Res*. 2004; 6: R170-9.
106. Messina M, McCaskill-Stevens W, Lampe JW. Addressing the soy and breast cancer relationship: review, commentary, and workshop proceedings. *J Natl Cancer Inst*. 2006; 98: 1275-84.
107. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. *JAMA*. 2002; 288: 321-33.
108. Boyd NF, Lockwood GA, Martin LJ, Byng JW, Yaffe MJ, Tritchler DL. Mammographic density as a marker of susceptibility to breast cancer: a hypothesis. *IARC Sci Publ*. 2001; 154: 163-9.
109. Boyd NF, Martin LJ, Li Q, Sun L, Chiarelli AM, Hisslop G, Yaffe MJ, Minkin S. Mammographic density as a surrogate marker for the effects of hormone therapy on risk of breast cancer. *Cancer Epidemiol Biomarkers Prev*. 2006; 15: 961-6.
110. Shu XO, Zheng Y, Cai H, Gu K, Chen Z, Zheng W, Lu W. Soy food intake and breast cancer survival. *JAMA*. 2009; 302: 2437-43.
111. Kang X, Zhang Q, Wang S, Huang X, Jin S. Effect of soy isoflavones on breast cancer recurrence and death for patients receiving adjuvant endocrine therapy. *CAJ*. 2010; 182: 1857-62.
112. Guha N, Kwan ML, Quesenberry CP, Jr., Weltzien EK, Castillo AL, Caan BJ. Soy isoflavones and risk of cancer recurrence in a cohort of breast cancer survivors: the Life After Cancer Epidemiology study. *Breast Cancer Res Treat*. 2009; 118: 395-405.
113. Caan BJ, Natarajan L, Parker B, Gold EB, Thomson C, Newman W, Rock CL, Pu M, Al-Delaimy W, et al. Soy food consumption and breast cancer prognosis. *Cancer Epidemiol Biomarkers Prev*. 2011; 20: 854-8.
114. Ballard-Barbash R, Neuhouser ML. Challenges in design and interpretation of observational research on health behaviors and cancer survival. *JAMA*. 2009; 302: 2483-4.
115. Ju YH, Doerge DR, Allred KF, Allred CD, Helferich WG. Dietary genistein negates the inhibitory effect of tamoxifen on growth of estrogen-dependent human breast cancer (MCF-7) cells implanted in athymic mice. *Cancer Res*. 2002; 62: 2474-7.
116. Ju YH, Doerge DR, Woodling KA, Hartman JA, Kwak J, Helferich WG. Dietary genistein negates the inhibitory effect of letrozole on the growth of aromatase-expressing estrogen-dependent human breast cancer cells (MCF-7Ca) in vivo. *Carcinogenesis*. 2008; 29: 2162-8.
117. Doyle C, Kushi LH, Byers T, Courneya KS, Demark-Wahnefried W, Grant B, McTiernan A, Rock CL, Thompson C, et al. Nutrition and physical activity during and after cancer treatment: an american cancer society guide for informed choices. *CA Cancer J Clin*. 2006; 56: 323-53.
118. Messina M, Abrams DJ, Hardy M. Can clinicians now assure their breast cancer patients that soyfoods are safe? *Women's Health (Lond Engl)*. 2010; 6: 335-8.
119. Johnson JM, Walker PM. Zinc and iron utilization in young women consuming a beef-based diet. *J Am Diet Assoc*. 1992; 92: 1474-8.
120. Thompson DB, Erdman JW. Phytic acid determination in soybeans. *J Food Sci*. 1982; 47: 513-517.
121. Urbano G, Lopez-Jurado M, Aranda P, Vidal-Valverde C, Tenorio E, Porres J. The role of phytic acid in legumes: antinutrient or beneficial function? *J Physiol Biochem*. 2000; 56: 283-94.
122. Sandstrom B, Cederblad A. Zinc absorption from composite meals. II. Influence of the main protein source. *Am J Clin Nutr*. 1980; 33: 1778-83.
123. Sandstrom B, Kivisto B, Cederblad A. Absorption of zinc from soy protein meals in humans. *J Nutr*. 1987; 117: 321-7.
124. Davidsson L, Almgren A, Sandstrom B, Juillerat M, Hurrell RF. Zinc absorption in adult humans: the effect of protein sources added to liquid test meals. *Br J Nutr*. 1996; 75: 607-13.
125. Lonerdal B, Cederblad A, Davidsson L, Sandstrom B. The effect of individual components of soy formula and cows' milk formula on zinc bioavailability. *Am J Clin Nutr*. 1984; 40: 1064-70.
126. de Portela ML, Weisstaub AR. Basal urinary zinc/creatinine ratio as an indicator of dietary zinc intake in healthy adult women. *J Am Coll Nutr*. 2000; 19: 413-7.
127. Hunt JR. Moving toward a plant-based diet: are iron and zinc at risk? *Nutr Rev*. 2002; 60: 127-34.
128. Messina V, Melina V, Mangels AR. A new food guide for North American vegetarians. *Can J Diet Pract Res*. 2003; 64: 82-6.
129. Messina V, Melina V, Mangels AR. A new food guide for North American vegetarians. *J Am Diet Assoc*. 2003; 103: 771-5.
130. Mangels AR, Messina V. Considerations in planning vegan diets: infants. *J Am Diet Assoc*. 2001; 101: 670-7.
131. Messina V, Mangels AR. Considerations in planning vegan diets: children. *J Am Diet Assoc*. 2001; 101: 661-9.
132. Messina VK, Burke KI. Position of the American Dietetic Association: vegetarian diets. *J Am Diet Assoc*. 1997; 97: 1317-21.
133. Karr-Lilienthal LK, Grieshop CM, Merchen NR, Mahan DC, Fahey GC, Jr. Chemical composition and protein quality comparisons of soybeans and soybean meals from five leading soybean-producing countries. *J Agric Food Chem*. 2004; 52: 6193-9.
134. Murray-Kolb LE, Welch R, Theil EC, Beard JL. Women with low iron stores absorb iron from soybeans. *Am J Clin Nutr*. 2003; 77: 180-4.
135. Lonerdal B, Bryant A, Liu X, Theil EC. Iron absorption from soybean ferritin in nonanemic women. *Am J Clin Nutr*. 2006; 83: 103-7.
136. Sandberg AS. Bioavailability of minerals in legumes. *Br J Nutr*. 2002; 88 Suppl 3: S281-5.
137. Heaney RP, Weaver CM, Fitzsimmons ML. Soybean phytate content: effect on calcium absorption. *Am J Clin Nutr*. 1991; 53: 745-7.
138. Weaver CM, Heaney RP, Connor L, Martin BR, Smith DL, Nielsen E. Bioavailability of calcium from tofu vs. milk in premenopausal women. *J Food Sci*. 2002; 68: 3144-3147.
139. Zhao Y, Martin BR, Weaver CM. Calcium bioavailability of calcium carbonate fortified soymilk is equivalent to cow's milk in young women. *J Nutr*. 2005; 135: 2379-82.
140. Tang AL, Walker KZ, Wilcox G, Strauss BJ, Ashton JF, Stojanovska L. Calcium absorption in Australian osteopenic postmenopausal women: an acute comparative study of fortified soymilk to cows' milk. *Asia Pac J Clin Nutr*. 2010; 19: 243-9.
141. Heaney RP, Dowell MS, Rafferty K, Bierman J. Bioavailability of the calcium in fortified soy imitation milk, with some observations on method. *Am J Clin Nutr*. 2000; 71: 1166-9.
142. Heaney RP, Rafferty K. The settling problem in calcium-fortified soybean drinks. *J Am Diet Assoc*. 2006; 106: 1753; author reply 1755.
143. Food and Drug Administration (FDA). Food Allergen Labeling and Consumer Protection (FALCP) Act of 2004 hwcfgaap. <http://www.cfsan.fda.gov/~acrobot/alrgact.pdf>.
144. Food and Drug Administration (FDA). Food Allergen Labeling and Consumer Protection (FALCP) Act of 2004. <http://www.cfsan.fda.gov/~acrobot/alrgact.pdf>, 2004.
145. Vierk KA, Koehler KM, Fain SB, Street DA. Prevalence of self-reported food allergy in American adults and use of food labels. *J Allergy Clin Immunol*. 2007; 119: 1504-10.
146. Savage JH, Kaeding AJ, Matsui EC, Wood RA. The natural history of soy allergy. *J Allergy Clin Immunol*. 2010; 125: 683-686.
147. Bhatia J, Greer F. Use of soy protein-based formulas in infant feeding. *Pediatrics*. 2008; 121: 1062-8.
148. Sladkevicius E, Nagy E, Lack G, Guest JF. Resource implications and budget impact of managing cow milk allergy in the UK. *J Med Econ*. 2010; 13: 119-28.
149. Dias A, Santos A, Pinheiro JA. Persistence of cow's milk allergy beyond two years of age. *Allergol Immunopathol (Madri)*. 2010; 38: 8-12.
150. Gilchrist JM, Moore MB, Andres A, Estroff JA, Badger TM. Ultrasonographic Patterns of Reproductive Organs in Infants Fed Soy Formula: Comparisons to Infants Fed Breast Milk and Milk Formula. *J Pediatr*. 2010; 156: 215-220.
151. Li J, Dykman RA, Jing H, Gilchrist JM, Badger TM, Pivik RT. Cortical responses to speech sounds in 3- and 6-month-old infants fed breast milk, milk formula, or soy formula. *Dev Neuropsychol*. 2010; 35: 762-84.
152. Pivik RT, Andres A, Badger TM. Diet and gender influences on processing and discrimination of speech sounds in 3- and 6-month-old infants: a developmental ERP study. *Dev Sci*. 2011; 14: 700-12.
153. Pivik RT, Andres A, Badger TM. Effects of diet on early stage cortical perception and discrimination of syllables differing in voice-onset time: A longitudinal ERP study in 3 and 6 month old infants. *Brain Lang*. 2012; 120: 27-41.
154. Messina M, Nagata C, Wu AH. Estimated Asian adult soy protein and isoflavone intakes. *Nutr Cancer*. 2006; 55: 1-12.
155. Rand WM, Pellett PL, Young VR. Meta-analysis of nitrogen balance studies for estimating protein requirements in healthy adults. *Am J Clin Nutr*. 2003; 77: 109-27.
156. Hughes GJ, Ryan DJ, Mukherjee R, Schasteen CS. Protein Digestibility-Corrected Amino Acid Scores (PDCAAS) for Soy Protein Isolates and Concentrate: Criteria for Evaluation. *J Agric Food Chem*. 2011; 59: 12707-12.
157. Murphy PA, Song T, Buseman G, Barua K, Beecher GR, Trainer D, Holden J. Isoflavones in retail and institutional soy foods. *J Agric Food Chem*. 1999; 47: 2697-704.
158. Kim J, Kang M, Lee JS, Inoue M, Sasazuki S, Tsugane S. Fermented and non-fermented soy food consumption and gastric cancer in Japanese and Korean populations: A meta-analysis of observational studies. *Cancer Sci*. 2011; 102: 231-44.
159. Yang WS, Va P, Wong MY, Zhang HL, Xiang YB. Soy intake is associated with lower lung cancer risk: results from a meta-analysis of epidemiologic studies. *Am J Clin Nutr*. 2011; 94: 1575-83.
160. Shurtleff W. Database search of tofu and Japan before 1900. Lafayette: The Soyfoods Center, 2003.
161. Shurtleff W. Database search of tofu and China before 1900. Lafayette: The Soyfoods Center, 2003.

The 69 farmer-directors of USB oversee the investments of the soy checkoff to maximize profit opportunities for all U.S. soybean farmers. These volunteers invest and leverage checkoff funds to increase the value of U.S. soy meal and oil, to ensure U.S. soybean farmers and their customers have the freedom and infrastructure to operate, and to meet the needs of U.S. soy's customers. As stipulated in the federal Soybean Promotion, Research and Consumer Information Act, the USDA Agricultural Marketing Service has oversight responsibilities for USB and the soy checkoff. For more information, please visit SoyConnection.com.